| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:407.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
From the Division of Cardiology, University of TexasHouston Medical School (P.R., M.E.Y., T.C.C., H.T.), and St Lukes Episcopal Hospital and Texas Heart Institute (O.H.F., H.T.), Houston, Tex.
Correspondence to Heinrich Taegtmeyer, MD, DPhil, Department of Internal Medicine, Division of Cardiology, University of Texas HoustonMedical School, 6431 Fannin, MSB 1.246, Houston, TX 77030. E-mail Heinrich.Taegtmeyer{at}uth.tmc.edu
Background In animal studies, diabetes has been shown to induce changes in gene expression of key regulators in cardiac energy metabolism and calcium homeostasis. In the present study, we tested the hypothesis that metabolic gene expression in nonischemic failing hearts of diabetic patients differs from that in nonischemic failing hearts of nondiabetic patients.
Methods and Results Left ventricular tissue was obtained from nonfailing hearts (n=6) and from nonischemic failing hearts of patients with or without type 2 diabetes. Myocardial transcript levels of key regulators in energy substrate metabolism (glucose transporter 1, glucose transporter 4, pyruvate dehydrogenase kinase 4, peroxisome proliferatoractivated receptor
, muscle carnitine palmitoyl transferase-1, medium-chain acyl-CoA dehydrogenase, and uncoupling protein 3), calcium homeostasis (sarcoplasmic reticulum Ca2+-ATPase [SERCA2a], phospholamban, and cardiac ryanodine receptor), and contractile function (myosin heavy chain
) were measured using real-time quantitative reverse transcriptionpolymerase chain reaction. In addition, we measured myocyte enhancer factor 2C (MEF2C) and SERCA2a protein levels. Only MEF2C regulated transcripts (glucose transporter 4, SERCA2a, and myosin heavy chain
) were lower in the diabetic group compared with the nondiabetic group. MEF2C protein content was also decreased.
Conclusion MEF2C and MEF2C-regulated genes are decreased in the failing hearts of diabetic patients. This transcriptional mechanism may contribute to the contractile dysfunction in heart failure patients with diabetes.
Key Words: diabetes mellitus cardiomyopathy metabolism polymerase chain reaction
This article has been cited by other articles:
![]() |
M. R. MacDonald, M. C. Petrie, F. Varyani, J. Ostergren, E. L. Michelson, J. B. Young, S. D. Solomon, C. B. Granger, K. Swedberg, S. Yusuf, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme Eur. Heart J., June 1, 2008; 29(11): 1377 - 1385. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Witteles and M. B. Fowler Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options J. Am. Coll. Cardiol., January 15, 2008; 51(2): 93 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Giger, A. X. Qin, P. W. Bodell, K. M. Baldwin, and F. Haddad Activity of the beta-myosin heavy chain antisense promoter responds to diabetes and hypothyroidism Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3065 - H3071. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Aragno, R. Mastrocola, C. Medana, M. G. Catalano, I. Vercellinatto, O. Danni, and G. Boccuzzi Oxidative Stress-Dependent Impairment of Cardiac-Specific Transcription Factors in Experimental Diabetes Endocrinology, December 1, 2006; 147(12): 5967 - 5974. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Pruimboom-Brees, M. Haghpassand, L. Royer, D. Brees, C. Aldinger, W. Reagan, J. Singh, R. Kerlin, C. Kane, S. Bagley, et al. A Critical Role for Peroxisomal Proliferator-Activated Receptor-{alpha} Nuclear Receptors in the Development of Cardiomyocyte Degeneration and Necrosis Am. J. Pathol., September 1, 2006; 169(3): 750 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Herrero, L. R. Peterson, J. B. McGill, S. Matthew, D. Lesniak, C. Dence, and R. J. Gropler Increased Myocardial Fatty Acid Metabolism in Patients With Type 1 Diabetes Mellitus J. Am. Coll. Cardiol., February 7, 2006; 47(3): 598 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Golfman, C. R. Wilson, S. Sharma, M. Burgmaier, M. E. Young, P. H. Guthrie, M. Van Arsdall, J. V. Adrogue, K. K. Brown, and H. Taegtmeyer Activation of PPAR{gamma} enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E328 - E336. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lemonnier and M. E. Buckingham Characterization of a Cardiac-specific Enhancer, Which Directs {alpha}-Cardiac Actin Gene Transcription in the Mouse Adult Heart J. Biol. Chem., December 31, 2004; 279(53): 55651 - 55658. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. SHARMA, J. V. ADROGUE, L. GOLFMAN, I. URAY, J. LEMM, K. YOUKER, G. P. NOON, O. H FRAZIER, and H. TAEGTMEYER Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart FASEB J, November 1, 2004; 18(14): 1692 - 1700. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Simoes, S. Egert, S. Ziegler, M. Miyagawa, S. Reder, T. Lehner, N. Nguyen, M. J. Charron, and M. Schwaiger Delayed response of insulin-stimulated fluorine-18 deoxyglucose uptake in glucose transporter-4-null mice hearts J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1690 - 1697. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. TAEGTMEYER, L. GOLFMAN, S. SHARMA, P. RAZEGHI, and M. VAN ARSDALL Linking Gene Expression to Function: Metabolic Flexibility in the Normal and Diseased Heart Ann. N.Y. Acad. Sci., May 1, 2004; 1015(1): 202 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ventura-Clapier, A. Garnier, and V. Veksler Energy metabolism in heart failure J. Physiol., February 15, 2004; 555(1): 1 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Bidasee, Y. Zhang, C. H. Shao, M. Wang, K. P. Patel, U. D. Dincer, and H. R. Besch Diabetes Increases Formation of Advanced Glycation End Products on Sarco(endo)plasmic Reticulum Ca2+-ATPase Diabetes, February 1, 2004; 53(2): 463 - 473. [Abstract] [Full Text] |
||||
![]() |
M. van Bilsen, P. J.H Smeets, A. J Gilde, and G. J van der Vusse Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res, February 1, 2004; 61(2): 218 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Taegtmeyer and P. Razeghi Heart disease in diabetes--resist the beginnings J. Am. Coll. Cardiol., January 21, 2004; 43(2): 315 - 315. [Full Text] [PDF] |
||||
![]() |
P. Razeghi and H. Taegtmeyer Activity of the Akt/GSK-3{beta} pathway in the failing human heart before and after left ventricular assist device support Cardiovasc Res, January 1, 2004; 61(1): 196 - 197. [Full Text] [PDF] |
||||
![]() |
J. Chang, L. Wei, T. Otani, K. A. Youker, M. L. Entman, and R. J. Schwartz Inhibitory Cardiac Transcription Factor, SRF-N, Is Generated by Caspase 3 Cleavage in Human Heart Failure and Attenuated by Ventricular Unloading Circulation, July 29, 2003; 108(4): 407 - 413. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Bidasee, K. Nallani, Y. Yu, R. R. Cocklin, Y. Zhang, M. Wang, U. D. Dincer, and H. R. Besch Jr. Chronic Diabetes Increases Advanced Glycation End Products on Cardiac Ryanodine Receptors/Calcium-Release Channels Diabetes, July 1, 2003; 52(7): 1825 - 1836. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xia, H. Y. Wen, M. E. Young, P. H. Guthrie, H. Taegtmeyer, and R. E. Kellems Mammalian Target of Rapamycin and Protein Kinase A Signaling Mediate the Cardiac Transcriptional Response to Glutamine J. Biol. Chem., April 4, 2003; 278(15): 13143 - 13150. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Taegtmeyer Switching Metabolic Genes to Build a Better Heart Circulation, October 15, 2002; 106(16): 2043 - 2045. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |